{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:20:46Z","timestamp":1772810446857,"version":"3.50.1"},"reference-count":49,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.2217\/14796694.1.5.609","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T11:04:12Z","timestamp":1133435052000},"page":"609-618","source":"Crossref","is-referenced-by-count":4,"title":["Anagrelide for Control of Thrombocytosis Due to Myeloproliferative Disorders"],"prefix":"10.1080","volume":"1","author":[{"given":"Claire N","family":"Harrison","sequence":"first","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust,St Thomas\u2019 Hospital,\rLambeth Palace Road,\rLondon,\rSE1 7EH,\rUK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,9,22]]},"reference":[{"key":"e_1_3_1_3_1_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008859730818"},{"key":"e_1_3_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_3_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_1_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_3_1_3_7_1","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.","volume":"85","author":"Passamonti F","year":"2000","unstructured":"Passamonti F , BrusamolinoE, LazzarinoMet al.: Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.Haematologica85, 1011\u20131018 (2000).","journal-title":"Haematologica"},{"key":"e_1_3_1_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_3_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996122"},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(03)00082-0"},{"key":"e_1_3_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05535.x"},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_3_1_3_13_1","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.","volume":"89","author":"Barbui T","year":"2004","unstructured":"Barbui T , BarosiG, GrossiAet al.: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.Haematologica89, 215\u2013232 (2004).","journal-title":"Haematologica"},{"key":"e_1_3_1_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3370"},{"key":"e_1_3_1_3_15_1","first-page":"24","article-title":"Management of polycythemia vera with hydroxyurea.","volume":"34","author":"TatarskyI","year":"1997","unstructured":"TatarskyI , Sharon,R: Management of polycythemia vera with hydroxyurea.Semin. Hematol.34, 24\u201328 (1997).","journal-title":"Semin. Hematol."},{"key":"e_1_3_1_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0135"},{"key":"e_1_3_1_3_17_1","first-page":"2224","volume-title":"J. Clin. Oncol.","author":"Marchioli","year":"2005","unstructured":"Marchioli et al. : Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.J. Clin. Oncol.23, 2224\u20132232 (2005)."},{"key":"e_1_3_1_3_18_1","first-page":"348a","article-title":"Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythaemia in a retrospective study of the GIMMC group in two thousand patients. (Abstract).","volume":"90","author":"Gugliotta L","year":"1997","unstructured":"Gugliotta L , MarchioliR, FiacchiniM: Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythaemia in a retrospective study of the GIMMC group in two thousand patients. (Abstract).Blood90, 348a (1997).","journal-title":"Blood"},{"key":"e_1_3_1_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_3_1_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"e_1_3_1_3_21_1","first-page":"814","article-title":"Treatment of essential thrombocythemia during pregnancy with interferon-alpha.","volume":"87","author":"Delage R","year":"1996","unstructured":"Delage R , DemersC, CantinG, RoyJ: Treatment of essential thrombocythemia during pregnancy with interferon-alpha.Obstet. Gynecol.87, 814\u2013817 (1996).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_1_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05400.x"},{"key":"e_1_3_1_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_3_1_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4248"},{"key":"e_1_3_1_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0651-7"},{"key":"e_1_3_1_3_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.6.1107"},{"key":"e_1_3_1_3_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996111"},{"key":"e_1_3_1_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.8.1931.1931"},{"key":"e_1_3_1_3_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3503164.x"},{"key":"e_1_3_1_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706341"},{"key":"e_1_3_1_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1602"},{"key":"e_1_3_1_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.52"},{"key":"e_1_3_1_3_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447050-00007"},{"key":"e_1_3_1_3_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1661206"},{"key":"e_1_3_1_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"e_1_3_1_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.10.002"},{"key":"e_1_3_1_3_37_1","first-page":"520","article-title":"Adverse effects and benefits of two\u00a0years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.","volume":"89","author":"Birgegard G","year":"2004","unstructured":"Birgegard G , BjorkholmM, KuttiJet al.: Adverse effects and benefits of two\u00a0years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.Haematologica89, 520\u2013527 (2004).","journal-title":"Haematologica"},{"key":"e_1_3_1_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1999.tb01585.x"},{"key":"e_1_3_1_3_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2004.00637.x"},{"key":"e_1_3_1_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.4.863"},{"key":"e_1_3_1_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_3_1_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_3_1_3_43_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.8.1781"},{"key":"e_1_3_1_3_44_1","first-page":"23","article-title":"Treatment of essential thrombocythemia with anagrelide.","volume":"36","author":"Silverstein MN","year":"1999","unstructured":"Silverstein MN , TefferiA: Treatment of essential thrombocythemia with anagrelide.Semin. Hematol.36, 23\u201325 (1999).","journal-title":"Semin. Hematol."},{"key":"e_1_3_1_3_45_1","first-page":"1130","article-title":"Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.","volume":"88","author":"Thiele J","year":"2003","unstructured":"Thiele J , KvasnickaHM, FuchsNet al.: Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.Haematologica, 88, 1130\u20131138 (2003).","journal-title":"Haematologica"},{"key":"e_1_3_1_3_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01598.x"},{"key":"e_1_3_1_3_47_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03688.x"},{"key":"e_1_3_1_4_2_1","unstructured":"www.ctsu.ox.ac.uk\/projects\/pt1\/(Accessed September2005)"},{"key":"e_1_3_1_4_3_1","unstructured":"www.anahydret.at (Accessed September2005)"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.1.5.609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:15Z","timestamp":1719125055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.1.5.609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,22]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.2217\/14796694.1.5.609"],"URL":"https:\/\/doi.org\/10.2217\/14796694.1.5.609","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,22]]}}}